InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (36 ops.)
Insider track record
ExecutiveDisclosed buys
0
Disclosed sells
36
T+90 hit rate
69%
T+90 mean return
+6.5%
Across 16 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Browse the complete record of transactions filed by Boulding Mark Elliott, Vice-Président Exécutif et Directeur Juridique. Director active across 1 company, notably PTC Therapeutics, INC.. In total, 63 disclosures have been logged. Breakdown: 0 buy · 36 sells. Total volume traded: €2.3m. History available since 8 July 2021. The latest transaction was filed on 6 July 2026 (Levée d'options). Regulator: SEC (Form 4). The full history is openly available.
Declarations63 total
2,266 shares@ US$39.42Common StockSEC:0001578852-26-000020:0
313 shares@ US$83.10Common StockSEC:0001578852-26-000020:1
833 shares@ US$84.41Common StockSEC:0001578852-26-000020:2
519 shares@ US$85.84Common StockSEC:0001578852-26-000020:3
601 shares@ US$86.38Common StockSEC:0001578852-26-000020:4
2,813 shares@ US$46.54Common StockSEC:0001578852-26-000020:5
387 shares@ US$83.10Common StockSEC:0001578852-26-000020:6
1,036 shares@ US$84.41Common StockSEC:0001578852-26-000020:7
645 shares@ US$85.84Common StockSEC:0001578852-26-000020:8
745 shares@ US$86.38Common StockSEC:0001578852-26-000020:9
8,510 sharesCommon StockSEC:0001578852-26-000018:0
6,600 sharesCommon StockSEC:0001578852-26-000018:1
1,850 sharesCommon StockSEC:0001578852-26-000018:2
2,012 sharesCommon StockSEC:0001578852-26-000018:3
1,703 sharesCommon StockSEC:0001578852-26-000018:4
309 sharesCommon StockSEC:0001578852-26-000018:5
2,265 shares@ US$39.421.5% of flowCommon StockSEC:0001578852-26-000012:0
822 shares@ US$68.911.0% of flowCommon StockSEC:0001578852-26-000012:1
1,443 shares@ US$69.751.7% of flowCommon StockSEC:0001578852-26-000012:2
18,124 shares@ US$39.4212.5% of flowCommon StockSEC:0001578852-25-000005:0
3,100 shares@ US$64.433.5% of flowCommon StockSEC:0001578852-25-000005:1
6,124 shares@ US$65.477.0% of flowCommon StockSEC:0001578852-25-000005:2
7,400 shares@ US$66.448.6% of flowCommon StockSEC:0001578852-25-000005:3
1,500 shares@ US$67.151.8% of flowCommon StockSEC:0001578852-25-000005:4
2,266 shares@ US$39.421.6% of flowCommon StockSEC:0001578852-25-000005:5
25 of 63 declarations
About Boulding Mark Elliott
Mark E. Boulding is Executive Vice President and Chief Legal Officer of PTC Therapeutics, a role he has held since March 2012. He joined PTC in 2002 after serving as General Counsel, Executive Vice President and Secretary of MedicaLogic/Medscape, and earlier worked as a partner at two Washington, D.C. law firms. PTC says he earned a B.A. from Yale College and a J.D. from the University of Michigan. Sources : https://www.ptcbio.com/team/leadership/mark-e-boulding/
